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Abstract 
Background: To describe the development and the psychometric properties of the Istituto Superiore di Sanità-HIV 
symptoms scale (lSS-HIV symptoms scale).
Methods: The ISS-HIV symptom scale was developed by an Italian working team including researchers, physicians 
and people living with HIV. The development process went through the following steps: (1) review of HIV/AIDS litera-
ture; (2) focus group; (3) pre-test analysis; (4) scale validation.
Results: The 22 symptoms of HIV-ISS symptoms scale were clustered in five factors: pain/general discomfort (7 
items); depression/anxiety (4 items); emotional reaction/psychological distress (5 items); gastrointestinal discomfort (4 
items); sexual discomfort (2 items). The internal consistence reliability was for all factors within the minimum accepted 
standard of 0.70.
Conclusions: The results of this study provide a preliminary evidence of the reliability and validity of the ISS-HIV 
symptoms scale. In the new era where HIV infection has been transformed into a chronic diseases and patients are 
experiencing a complex range of symptoms, the ISS-HIV symptoms scale may represent an useful tool for a compre-
hensive symptom assessment with the advantage of being easy to fill out by patients and potentially attractive to 
physicians mainly because it is easy to understand and requires short time to interpret the results.
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Background
The physician’s assessment was for a long time the only 
factor that affected health care decisions, however in 
more recent years the necessity for a closer coopera-
tion between physician and patient has been recognized. 
In this contest a key role is represented by the patient 
reported outcomes (PROs). Food and Drug Administra-
tion (FDA) defined PROs as any report coming directly 
from patients about their health condition and treat-
ment [1]. PROs can be used to measure overall concepts 
(e.g. state of general health), presence and intensity of 
specific symptoms, complex concepts, like the health 
related quality of life (HRQoL) [2–11]. In the field of HIV 
disease, symptoms play a central role in the life of HIV 
patients: they are the first reason the patient asks for care; 
they are strongly associated with HRQoL; they represent 
the patients experience of the drug adverse effects and 
disease effects [12–16]. Effective symptom management, 
aimed to decrease the burden of symptoms, could have 
a direct impact on improving the HRQoL and also an 
indirect impact on improving the adherence to antiret-
roviral therapy (ART) with expected positive impact on 
the efficacy of the treatment [17–20]. Moreover the clini-
cal interpretation of the symptoms is easily understood 
by physicians with a likely immediate effect in clinical 
practice [21]. It has also been shown that the symptoms 
reported directly by patients are more complete and 
more strongly associated with HRQoL than provider-
reported symptoms. [6]. It is therefore necessary that the 
presence and impact of symptoms are reported directly 
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by the patient through the use of specific tools. An HIV 
specific symptom checklist might be the most suitable 
tool for routine clinical use [21]. In the present paper we 
describe the development and the psychometric prop-
erties of the Istituto Superiore di Sanità-HIV symptoms 
scale (lSS-HIV symptoms scale).
Methods
The ISS-HIV symptom scale was developed by an Italian 
working team (coordinated by the Italian National Insti-
tute of Health, the ISS), including researchers, physicians 
and people living with HIV. The development process 
went through the following steps:
1. Review of existing HIV/AIDS literature
The first step in the development of the ISS-HIV symp-
toms scale was to review the symptoms measures avail-
able in literature. As a result of regular meeting the 
working team identified a list of symptoms to be included 
in the instrument.
2. Focus group
Two focus groups were conducted on independent 
groups of approximately 10 HIV infected people. The 
patients were recruited both in clinical centers and 
patients’ associations. The work done by focus groups 
resulted in a first draft of 38 HIV-related symptoms 
including.
3. Pre‑test analysis
The first draft of the symptoms list was tested in a cross-
sectional study on a group of 200 HIV + people, taking 
ART, recruited in two Italian clinical centers (Azienda 
Ospedaliera Universitaria Ospedali Riuniti, Ancona; 
Ospedale S. Maria della Misericordia, Perugia). Fre-
quency analysis of symptoms and an exploratory princi-
pal components factor analysis were conducted. Based 
on these results, the preliminary item list has then been 
modified. Twenty-two of the 38 original symptoms were 
retained for the final version of the symptoms list.
4. HIV‑ISS symptoms scale validation and final structure
A sample of 161 HIV  +  people on ART, enrolled in a 
cross-sectional study, from the two Italian clinical cent-
ers (Azienda Ospedaliera Universitaria Ospedali Riuniti, 
Ancona; Ospedale S. Maria della Misericordia, Perugia), 
was used to carry out the validation analysis. This study 
received ethics approval, and all patients provided writ-
ten informed consent (name of the Ethical Committee: 
Istituto Superiore di Sanità, Ethical Review Board). The 
sample was defined on the basis of common practice in 
psychometric studies, according to which at least five 
cases for each item should be provided. In this study 
the case-to-item ration was approximately 7.3. The final 
version of HIV-ISS symptoms scale resulted in a self- 
administered list of 22 symptoms. A Likert five-point 
intensity scale was used to evaluate the impact of symp-
toms (Appendix).
Statistical analysis
The statistical analyses reported in this study refer to 
validation analysis of HIV-ISS symptom scale includ-
ing psychometric assumptions of validity and reliabil-
ity [22]. An instrument is said to be valid if it measures 
what it is supposed to measure. For this purpose we 
focused on the concurrent validity and construct valid-
ity. The construct validity of the HIV-ISS symptoms 
scale was assessed using principal components fac-
tor analysis with varimax rotation. As for concurrent 
validity, a step-wise multiple regressions were used to 
examine the relationship between the HIV-ISS symp-
toms scale and an external and independent measure of 
HRQoL. For this purpose the ISSQoL (Istituto Superi-
ore di Sanità-Quality of Life), a validated specific ques-
tionnaire designed for people living with HIV, was used 
[23, 24]. The ISSQoL questionnaire includes 9 domains: 
physical functioning, role functioning, depression/
anxiety, energy/vitality, health distress, cognitive func-
tioning, social functioning, sexual life and satisfaction 
with quality of life. Reliability is defined as the degree 
to which repeated administration of a measurement 
instrument produces equivalent results under con-
trolled conditions. In the present study the Cronbach’s 
α coiffecient was used as an estimate of the test reliabil-
ity. The range between 0.70 and 0.90 is considered as the 
minimum required value.
Results—validation analysis
Description of the sample
The characteristics of the sample used for the valida-
tion analysis are shown in Table  1. The majority were 
men (75.8 %); 42.9 % were heterosexual. Median age was 
49  years old. About more than half of the participants 
were asymptomatic (56.5 %) and they were HIV infected 
for a median of 13.5 years. Median HIV viral load was 1.6 
log and median CD4 cell count was 611 cells/mm3.
Construct validity
The 22 symptoms of HIV-ISS symptoms scale were clus-
tered in five factors that explained 64.96  % of variance 
(Table  2): pain/general discomfort (7 items);depression/
anxiety (4 items); emotional reaction/psychologi-
cal distress (5 items); gastrointestinal discomfort (4 
items);sexual discomfort (2 items);
Page 3 of 7Bucciardini et al. AIDS Res Ther  (2016) 13:18 
Reliability
The Chronbach’s α scores were for all factors within the 
minimum accepted standard of 0.70 (Table 2).
Concurrent validity
Step-wise multiple regressions were used for each 
ISSQoL domain as dependent variable and the five fac-
tors of the HIV-ISS symptoms scale as predictor vari-
ables. The HIV-ISS symptoms scale concurrent validity 
was tested based on the following hypothesized sig-
nificant relationships: (1) pain/general discomfort with 
physical functioning, social functioning, depression/
anxiety, energy/vitality, sexual life and satisfaction with 
quality of life; (2) depression/anxiety with all ISSQoL 
domains; (3) emotional reaction/psychological distress 
with social functioning, depression/anxiety, energy/
vitality, cognitive functioning, satisfaction with quality 
of life; (4) gastrointestinal discomfort with social func-
tioning, depression/anxiety, energy/vitality; (5) sexual 
discomfort with social functioning, depression/anxiety, 
sexual life, satisfaction with quality of life. All hypoth-
esized relationships were confirmed (Table 3).
Discussion
The results of this study provide a preliminary evidence 
of the reliability and validity of the 22-item ISS-HIV 
symptoms scale. Factor analysis showed a good evidence 
for construct validity and internal consistency reliability. 
A good concurrent validity was also demonstrated. The 
regression analysis supported the evidence for the con-
current validity of the ISS-HIV symptoms scale factors 
with the ISSQoL domains. In the new era where HIV 
infection has been transformed into a chronic diseases 
and patients are experiencing a complex range of symp-
toms due to HIV infection, side effects of antiretroviral 
therapy (ART) and also associated comorbidities, the 
Table 1 Characteristics of the population used for the vali-
dation analysis
Sex n (%)
 Female 39 (24.2)
 Male 122 (75.8)
Age (years)
 Mean ± SD (n, range) 49.0 ± 9.8 (161, 25–77)
 Median 49.0
Transmission route, n (%)
 Men having sex with men 60 (37.3)
 Intravenous drug users 26 (16.1)
 Heterosexual 69 (42.9)
 Other 6 (3.7)
HIV status, n (%)
 Asymptomatic (CDC A) 91 (56.5)
 Symptomatic (CDC B 47 (29.2)
 AIDS (CDC C) 23 (14.3)
Time from HIV diagnosis (years)
 Mean ± SD (n, range) 13.4 ± 9.2 (160, 0–30)
 Median 13.5
CD4 (cells/mm3)
 Mean ± SD (n, range) 652 ± 312 (161, 24–1686)
 Median 611
HIV-RNA cp/ml (log10)
 Mean ± SD (n, range) 1.76 ± 0.6 (161, 1–6)
 Median 1.60
Table 2 Factor structure and reliability estimates
ISS‑HIV symptom scales 
Items
Loadings % Variance Chronbach’s α
Factor 1: Pain/general discom-
fort (7 items)
16.25 0.86
Pain in the head or feet 0.769
Aching muscles 0.691
Abnormal accumulation of fat 0.681
Abdominal bloating 0.563
Sweating 0.513
Impaired vision 0.498
Headache 0.475
Factor 2: Depression, anxiety 
(4 items)
16.03 0.87
Feeling sad 0.817
Worrying 0.758
Feeling anxious and nervous 0.718
Sleep problems 0.574
Factor 3: Emotional reaction/
psychological distress (5 
items)
13.08 0.83
Memory problems 0.739
Coughing 0.692
Shortness of breath 0.608
Difficulty in concentrating 0.591
Tiredness 0.488
Factor 4: Gastrointestinal 
discomfort (4 items)
10.02 0.70
Weight loss 0.715
Lack of appetite 0.702
Diarrhoea 0.656
Heartburn 0.508
Factor 5: Sexual discomfort  
(2 items)
9.58 0.91
Decrease of sexual  
interest
0.790
Problem with sexual activity 0.758
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Table 3 Regression analysis between ISS-HIV factors scores and ISS-Qol questionnaire
ISSQoL domains  
(dependent variables)
ISS-HIV factors score (predictors) Standardized
coefficients (Beta)
p
Physical functioning Factor 1—Pain/general discomfort 0.25 0.001
Factor 2—Depression, anxiety 0.23 0.001
Factor 3—Emotional reaction/psychological distress 0.16 0.030
Factor 4—Gastrointestinal discomfort 0.13 0.068
Factor 5—Sexual discomfort 0.29 0.000
Role functioning Factor 1—Pain/general discomfort −0.02 0.827
Factor 2—Depression, anxiety 0.23 0.005
Factor 3—Emotional reaction/psychological distress 0.17 0.033
Factor 4—Gastrointestinal discomfort 0.09 0.262
Factor 5—Sexual discomfort 0.17 0.039
Social functioning Factor 1—Pain/general discomfort 0.22 0.001
Factor 2—Depression, anxiety 0.42 0.000
Factor 3—Emotional reaction/psychological distress 0.19 0.004
Factor 4—Gastrointestinal discomfort 0.19 0.005
Factor 5—Sexual discomfort 0.22 0.001
Depression/anxiety Factor 1—Pain/general discomfort 0.33 0.000
Factor 2—Depression, anxiety 0.65 0.000
Factor 3—Emotional reaction/psychological distress 0.26 0.000
Factor 4—Gastrointestinal discomfort 0.23 0.000
Factor 5—Sexual discomfort 0.27 0.000
Energy/vitality Factor 1—Pain/general discomfort 0.19 0.002
Factor 2—Depression, anxiety 0.40 0.000
Factor 3—Emotional reaction/psychological distress 0.41 0.000
Factor 4—Gastrointestinal discomfort 0.16 0.009
Factor 5—Sexual discomfort 0.13 0.032
Health distress Factor 1—Pain/general discomfort 0.22 0.000
Factor 2—Depression, anxiety 0.58 0.000
Factor 3—Emotional reaction/psychological distress 0.06 0.353
Factor 4—Gastrointestinal discomfort 0.17 0.006
Factor 5—Sexual discomfort 0.23 0.000
Cognitive functioning Factor 1—Pain/general discomfort 0.19 0.001
Factor 2—Depression, anxiety 0.46 0.000
Factor 3—Emotional reaction/psychological distress 0.39 0.000
Factor 4—Gastrointestinal discomfort 0.17 0.004
Factor 5—Sexual discomfort 0.19 0.001
Sexual life Factor 1—Pain/general discomfort 0.22 0.002
Factor 2—Depression, anxiety 0.35 0.000
Factor 3—Emotional reaction/psychological distress 0.03 0.623
Factor 4—Gastrointestinal discomfort −0.05 0.459
Factor 5—Sexual discomfort 0.39 0.000
Satisfaction with quality of life Factor 1—Pain/general discomfort 0.29 0.000
Factor 2—Depression, anxiety 0.46 0.000
Factor 3—Emotional reaction/psychological distress 0.14 0.033
Factor 4—Gastrointestinal discomfort 0.07 0.285
Factor 5—Sexual discomfort 0.19 0.003
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ISS-HIV symptoms scale may represent an updated and 
useful tool for a comprehensive symptom assessment and 
control in clinical practice.
Routine use of the symptoms assessment in the clini-
cal practice could improve the communication between 
patient and clinician and this would make it possible to 
take targeted actions to manage the presence of particu-
lar symptom clusters [3, 25]. The use of patient-reported 
symptoms in clinical practice could not only improve 
clinician-patient communication, but also would allow to 
understand the changes in patient well-being over time, 
leading clinicians to therapeutic choices targeted to indi-
vidual patients with a positive effect on individual patient 
management and outcomes [26–29]. The ISS-HIV symp-
toms scale has the advantage of being easy to fill out by 
patients and potentially attractive to physicians mainly 
because it is easy to understand and requires short time 
to interpret the results. The ISS-HIV Symptom Scale 
can be suitable for routine use in clinical practice, both 
as a single screening tool and in conjunction with other 
specific instruments. The simultaneous use of multiple 
instruments can be strategically significant in the pres-
ence of high-impact specific symptoms. The ISS-HIV 
Symptom Scale is able to detect the most frequent symp-
toms, as well as symptoms that may highly affect the 
patient’s quality of life. More specific instruments, such 
as those for pain or anxiety detection, could then be used 
to achieve more accurate information.
Considering also the recent agenda by the Patient-Cen-
tered Outcomes Research Institute (PCORI) that calls 
for a greater involvement of patients in assessing health 
care options, the systematic collection of PROs should be 
widely recommended [30]. As some experts in outcomes 
research have already experienced, a website, where PRO 
measures are collected in electronic health records (EHR) 
and linked to electronic medical record (EMR), can be a 
useful innovative tool to improve and stimulate the use of 
patient reported data in clinical practice [31, 32]. Clini-
cians would have the advantage to use PROs measure as 
a part of patients information along with laboratory and 
clinical data. The HIV-ISS symptoms scale, a short and 
comphrensive list of symptoms and easy to administer 
both by patients and clinicians, may be suitable for this 
purpose. The present study has several limitations. First, 
the construct validity of HIV-ISS Symptoms scale has not 
been supported by a confirmatory factor analysis. Moreo-
ver, a responsiveness assessment of the instrument would 
also be necessary. Generalization of results is limited to 
the Italian context where the validation analysis has been 
performed. Additional studies should address the repro-
ducibility of index symptoms.
Conclusions
The results of this study show that ISS-HIV symptoms 
scale is a self-administered tool, with characteristics of 
validity and reliability, able to provide useful measures 
patient-centered. A more complete detection of symp-
toms and their appropriate management may positively 
impact on the HRQoL of the patients and, indirectly, 
increase adherence to ART with expected positive impact 
on the efficacy of the treatment.
Abbrevations
PROs: patient reported outcomes; HRQoL: health related quality of life; ART: 
antiretroviral therapy; lSS-HIV symptoms scale: Istituto Superiore di Sanità-HIV 
symptoms scale; ISSQoL: Istituto Superiore di Sanità-Quality of Life; PCORI: 
Patient-Centered Outcomes Research Institute; EHR: electronic health records; 
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